Rationale for Cotargeting Hepatocyte Growth Factor and Epidermal Growth Factor Receptor in Recurrent/Metastatic Head and Neck Cancer

J Clin Oncol. 2023 Aug 1;41(22):3863-3866. doi: 10.1200/JCO.23.00460. Epub 2023 Jun 15.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ErbB Receptors / genetics
  • ErbB Receptors / metabolism
  • Head and Neck Neoplasms* / drug therapy
  • Hepatocyte Growth Factor*
  • Humans
  • Neoplasm Recurrence, Local / drug therapy

Substances

  • Hepatocyte Growth Factor
  • ErbB Receptors